Risk Factors for Multidrug Resistant Bacteria at ICU Admission
NCT05983861 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2023-08-09
Summary
The objective of this single-center prospective observational study is to evaluate possible independent risk factors for multidrug-resistant (MDR) bacteria upon ICU admission by analyzing comorbidities, epidemiological data, and laboratory/microbiological information of the subjects.
Conditions
- Multi Drug Resistant Bacteria
Interventions
- DIAGNOSTIC_TEST
-
Identification o Multi Drug Resistant Bacteria
Identification o Multi Drug Resistant Bacteria
Sponsors & Collaborators
-
José Raimundo Araujo de Azevedo
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-01
- Primary Completion
- 2024-08-31
- Completion
- 2025-01-31
More Related Trials
-
Impact of Performing a Rapid Antibiotic Susceptibility Test on Antibiotic Therapy Adaptation in Adult Patients with Enterobacterales Bacteremia
NCT06425367 ·Status: RECRUITING ·Phase: NA
-
Antimicrobial Stewardship Reduces MDRO Isolates in Critically Ill Patients
NCT02128399 ·Status: COMPLETED
-
Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections
NCT05942157 ·Status: RECRUITING ·Phase: NA
-
Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis
NCT03681431 ·Status: COMPLETED ·Phase: PHASE2
-
Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections
NCT06843668 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia
NCT01805284 ·Status: COMPLETED ·Phase: PHASE4
-
Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia
NCT03581370 ·Status: RECRUITING ·Phase: PHASE3
-
Reduction of Bacteriuria in Subjects Practicing Intermittent Catheterization
NCT01143116 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
NCT05210439 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections
NCT02060513 ·Status: COMPLETED
-
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
NCT03510351 ·Status: COMPLETED
-
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
NCT00519025 ·Status: COMPLETED
-
Clinical Impact of Rapid AST Directly From Blood Cultures
NCT03992703 ·Status: COMPLETED
-
The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
NCT00811980 ·Status: COMPLETED
-
Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use
NCT03489330 ·Status: COMPLETED
-
Incidence of Colonization by Multidrug-resistant Organisms in Mechanically Ventilated Patients With Severe COVID-19
NCT05293418 ·Status: COMPLETED
-
The Role of the Microbiota in the Systemic Immune Response
NCT02340182 ·Status: COMPLETED ·Phase: NA
-
Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients
NCT05352997 ·Status: COMPLETED
-
Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
NCT03747497 ·Status: COMPLETED ·Phase: PHASE2
-
Linezolid-resistant Staphylococcus Epidermidis in ICU and Risk Factors Analysis
NCT03140410 ·Status: UNKNOWN
-
Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients
NCT01786161 ·Status: TERMINATED ·Phase: PHASE4
-
Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU
NCT05511129 ·Status: UNKNOWN
-
Trial of Antimicrobial Restraint in Presumed Pneumonia
NCT04438187 ·Status: COMPLETED ·Phase: NA
-
Therapeutic Drug Monitoring of Anti-infectious Drugs in Intensive Care Unit
NCT03339869 ·Status: UNKNOWN ·Phase: NA
-
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
NCT07202377 ·Status: NOT_YET_RECRUITING ·Phase: NA